Shots:
Q2’2025 highlights major acquisitions in the pharma and biotech industry along with collaboartion. The talk of the town remained Blueprint Medicines’ acquisition by Sanofi for ~$9.5B
The quarter highlighted Collaboartion, including Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid
PharmaShots brings the Quarterly digest compiling insights from…
